Core Insights - Public fund institutions have significantly increased their research activities in January, focusing on AI computing power, high-end medical technology, and new energy as the three core investment themes [1][3][5] Group 1: Research Activity - A total of 156 public fund institutions participated in A-share research in January, covering 486 stocks across 17 industries, with a total of 3,992 research instances [1] - Leading institutions such as Bosera Fund, Huaxia Fund, and Penghua Fund conducted the most research, with Bosera Fund leading at 116 instances [2] - The most researched stocks included Zhongji Xuchuang in the communications sector with 61 instances, followed by Aipeng Medical and Xiangyu Medical in the medical sector with 57 and 47 instances respectively [2] Group 2: Industry Focus - The electronics industry was the most researched, with 603 instances covering 71 stocks, followed by the machinery equipment industry with 591 instances covering 67 stocks [2][3] - Other industries such as medical biology, electric equipment, and basic chemicals also saw significant research activity, each exceeding 276 instances [3] Group 3: Emerging Trends - Brain-computer interfaces have emerged as a key focus within the high-end medical sector, driven by technological breakthroughs and commercial progress [4] - Companies like Aipeng Medical and Meihai Medical are actively engaging in brain-computer interface developments, with Aipeng Medical discussing advancements in brainwave technology [4] - The year 2026 is anticipated to be pivotal for the commercialization of invasive brain-computer interfaces, with several companies already in clinical stages [4]

来源：新浪证券-红岸工作室 2月2日，美好医疗跌1.13%，成交额3.17亿元，换手率2.72%，总市值174.70亿元。 异动分析 脑机接口+减肥药+CRO概念+医疗器械概念+人民币贬值受益 1、根据2025年12月12日互动易：公司正与下游脑机接口客户深入开展产品合作，协助客户实现从实验 室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小，具体客户合作细节涉及商业 机密不便回复。 资金分析 今日主力净流入-700.69万，占比0.02%，行业排名93/135，连续2日被主力资金减仓；所属行业主力净流 入-6.62亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-700.69万1250.93万-5495.78万4979.78万-6.99亿 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1.24亿，占总成交额的6.75%。 2、2025年10月22日投资者关系记录表：公司已与客户签订减肥笔订单，相关自动化产线已启动建设， 预计明年投入交付。 3、2023年9月1日公告：公司专注于医疗器械领域，为全球医疗器械百强客户以及细分市场龙头企业提 供CDMO和CRO的一站 ...

Group 1 - The core point of the article highlights that Jingzhida (精智达) received the highest number of institutional research visits among listed companies, with 170 institutions conducting research during the last working week of January [1][2] - Jingzhida signed a significant sales contract worth 1.311 billion yuan (including tax) for semiconductor testing equipment, which has garnered considerable market attention [1][3] - The order is seen as a strong validation of the company's long-term investments and its solid market position, especially amid tight delivery schedules from international suppliers [3] Group 2 - In January, over 600 listed companies disclosed records of institutional investor research, with Dajin Heavy Industry (大金重工) receiving the most visits at 209 institutions [3][4] - The electronic and mechanical equipment sectors have shown high levels of interest from institutional investors, with these industries leading in the number of research visits [5] - The overall trend indicates a sustained enthusiasm for institutional research in the machinery and computer sectors, with a notable focus on electronic and mechanical equipment industries [5]

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with significant net outflows from major and retail investors, while the company shows mixed financial performance indicators in the medical device industry [1][2][3]. Financial Performance - As of January 30, 2026, Meihao Medical's stock closed at 31.06 yuan, down 1.52%, with a trading volume of 100,200 hands and a transaction amount of 311 million yuan [1]. - In the last five days, the stock has seen fluctuations in net capital flow, with a net outflow of 16.94 million yuan from major funds and a net inflow of 38.80 million yuan from retail investors on January 30 [2]. - For the first three quarters of 2025, the company reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders decreased by 19.25% to 208 million yuan [3]. Industry Comparison - Meihao Medical's total market value is 17.669 billion yuan, which is higher than the industry average of 11.102 billion yuan, ranking 16th out of 127 companies in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) stands at 63.65, significantly lower than the industry average of 104.17, ranking 62nd [3]. - The gross profit margin of Meihao Medical is 39.34%, which is below the industry average of 50.94%, ranking 89th [3]. Investment Sentiment - In the last 90 days, seven institutions have rated Meihao Medical with a "buy" recommendation, with an average target price of 24.57 yuan [4].

Core Insights - The brain-computer interface (BCI) technology is at a critical industrial turning point, transitioning from academic exploration to commercial application, driven by policy and demand [1][4] - The medical field is the primary battlefield for BCI applications, accounting for 56% of the market, while non-medical sectors such as consumer, industrial, and education represent a combined 44%, indicating strong expansion potential [2][3] Industry Overview - BCI technology enables direct communication between the brain and external devices, facilitating bidirectional interaction from neural signals to control commands. The technology is categorized into invasive, semi-invasive, and non-invasive methods, with no absolute superiority among them; suitability depends on specific applications [1][3] - The global BCI market is projected to grow from $1.98 billion in 2023 to $7.63 billion by 2029, with China's market expected to reach 1.73 billion yuan in 2023, increasing its global share to 12.5% [2] Development Challenges - The BCI industry faces several challenges, including balancing high-throughput, high signal-to-noise ratio signal acquisition with long-term biocompatibility, and the need for breakthroughs in decoding algorithms and adaptive control precision [3] - Clinical challenges include the need for large-scale trials to verify the long-term safety and efficacy of invasive products, as well as the maturity of indication definitions, surgical standardization, and postoperative management systems [3] Global and Domestic Progress - The global BCI industry ecosystem is rapidly developing, with leading companies like Neuralink and Synchron innovating in high-throughput flexible implants and vascular interventions to enhance brain signal acquisition and interaction systems [4] - In China, significant progress has been made in system integration and application implementation, with a diverse enterprise matrix represented by companies such as Strong Brain Technology (non-invasive), Borui Kang (semi-invasive), and Xinwei Medical (interventional) [4] Relevant Companies - Key players in the primary market include Strong Brain Technology, Borui Kang, Ladder Medical, and others; in the secondary market, upstream companies like Maipu Medical and Meihao Medical, midstream companies like Xinwei Medical-B and Xiangyu Medical, and downstream companies like Sanbo Neuroscience are notable [5]

Core Viewpoint - Meihua Medical (301363) has shown a mixed financial performance with a slight increase in revenue but a significant decline in net profit for the first three quarters of 2025 [2] Financial Performance - For the first three quarters of 2025, Meihua Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year [2] - The net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [2] - The net profit excluding non-recurring items was 203 million yuan, down 17.85% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year [2] - The single-quarter net profit attributable to shareholders was 93.90 million yuan, an increase of 5.89% year-on-year [2] - The single-quarter net profit excluding non-recurring items was 92.70 million yuan, up 9.56% year-on-year [2] - The company's debt ratio stands at 11.43%, with investment income of 4.90 million yuan and financial expenses of -27.39 million yuan [2] - The gross profit margin is reported at 39.34% [2] Market Activity - As of January 29, 2026, Meihua Medical's stock closed at 31.54 yuan, with an increase of 0.38% [1] - The turnover rate was 5.84%, with a trading volume of 218,100 hands and a transaction amount of 712 million yuan [1] - On January 29, the net inflow of main funds was 36.86 million yuan, accounting for 5.18% of the total transaction amount [1] - Retail investors experienced a net outflow of 23.36 million yuan, representing 3.28% of the total transaction amount [1] Analyst Ratings - In the last 90 days, seven institutions have given buy ratings for Meihua Medical, with an average target price of 2.457 billion yuan [3]

1月29日上午，医疗器械板块再迎催化，脑机接口领域接连获2项重大标准立项。截至发稿，含"脑"量约 24%的医疗器械指数ETF（159898）盘中上涨0.88%、一度涨超1%；权重股奕瑞科技大涨6.61%，乐普 医疗涨超3%，成份股迪安诊断涨超7%，美好医疗、金域医学涨超5%，华大基因、祥生医疗等多股拉 升。 消息面上，1月28日消息，为满足监管急需，助推采用脑机接口技术的医疗器械高质量发展，经研究， 国家药监局批准《采用脑机接口技术的医疗器械范式设计与应用规范运动功能重建》《采用脑机接口技 术的医疗器械侵入式设备可靠性验证方法》等2项医疗器械行业标准制修订项目立项。 业内对此指出，这是对工信部等七部门此前发布的《关于推动脑机接口产业创新发展的实施意见》中标 准体系建设相关内容的具体落实，同时也结合行业反馈的共性难题实现了空白填补。 该机构分析强调，中证全指医疗器械指数精选103只成分股，重点聚焦创业板和科创板，覆盖医疗设 备、医疗耗材和体外诊断三大方向；指数质地纯粹，100%聚焦医疗器械细分板块，β属性纯正。"脑机 接口"概念暴露度达23.79%，对前沿医疗科技具备较好的布局优势；同时，指数成分股境外业务收入 ...

1月29日上午，医疗器械板块再迎催化，脑机接口领域接连获2项重大标准立项。截至发稿，含"脑"量约24%的医疗器械指数ETF（159898）盘中上涨 0.88%、一度涨超1%；权重股奕瑞科技大涨6.61%，乐普医疗涨超3%，成份股迪安诊断涨超7%，美好医疗、金域医学涨超5%，华大基因、祥生医疗等多股 拉升。 消息面上，1月28日消息，为满足监管急需，助推采用脑机接口技术的医疗器械高质量发展，经研究，国家药监局批准《采用脑机接口技术的医疗器械范式 设计与应用规范运动功能重建》《采用脑机接口技术的医疗器械侵入式设备可靠性验证方法》等2项医疗器械行业标准制修订项目立项。 业内对此指出，这是对工信部等七部门此前发布的《关于推动脑机接口产业创新发展的实施意见》中标准体系建设相关内容的具体落实，同时也结合行业反 馈的共性难题实现了空白填补。 此外，医疗器械指数ETF（159898）第四大权重股乐普医疗1月28日公告称，预计2025年归属于上市公司股东的净利润为8亿元-12亿元，比上年同期增长 223.97%-385.95%。主要因心血管植介入业务稳增、创新药及皮肤科等新兴板块贡献增量等。 万联证券指出，目前脑机接口正处于" ...

全球脑机接口玩家奋楫争先，产业化落地谱写投资蓝图 20260128 摘要 创新药领域，减肥、小核酸及 2L 疗法值得关注。减肥和 IO 赛道市场规 模达千亿美元级别，具弹性机会。小核酸赛道也因高景气度备受关注。 全年维度来看，医药板块值得重点关注。 脑机接口商业化处于起步阶段，是 2026 年投资主线。植入式临床进展 迅速，心伟医疗、爱鹏医疗和乐普医疗安全性具优势。非侵入式方面， 翔宇、迈兰德、创新医疗和诚益通等公司靠前。 政策支持对脑机接口行业发展起到重要引领作用，2025 年推出发展目 标与产业规划蓝图，确立收费项目立项，提高公立医院购买积极性，为 未来纳入医保铺平道路。 脑机接口产业链核心技术壁垒集中于中上游，包括硬件（电极、芯片）、 手术机器人及算法处理等。国产替代进程加速，美好医疗率先卡位上游 并开始代工侵入型电极。 Neuralink 需定制 ASIC 芯片，因通用芯片无法在处理上千通道信号的 同时控制功耗。其关键部分是模拟前端，需实现微弱神经信号的放大、 滤波和数字化。 Q&A 目前医药板块的投资机会主要集中在哪些方向？ 当前医药板块的投资机会主要集中在创新药及其相关产业链上。尤其是一些龙 头企 ...

Group 1 - The core viewpoint of the news is that Meihao Medical's stock price increased by 5.32% to 33.09 CNY per share, with a trading volume of 161 million CNY and a turnover rate of 1.33%, resulting in a total market capitalization of 18.824 billion CNY [1] - Meihao Medical, established on July 15, 2010, and listed on October 12, 2022, is located in Longgang District, Shenzhen, Guangdong Province, and specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The revenue composition of Meihao Medical includes: 59.48% from home respiratory machine components, 14.61% from home and consumer electronics components, 10.33% from other medical product components, 8.16% from cochlear implant components, 5.63% from precision molds and automation equipment, 1.09% from other categories, and 0.70% from proprietary products [1] Group 2 - Among the top circulating shareholders of Meihao Medical, Penghua Fund's Penghua New Emerging Industries Mixed A (206009) increased its holdings by 63,000 shares in the third quarter, now holding 3.5758 million shares, which accounts for 2.29% of the circulating shares [2] - The fund has a latest scale of 3.215 billion CNY, with a year-to-date return of 10.77%, ranking 2169 out of 8866 in its category, and a one-year return of 53.75%, ranking 1970 out of 8126 [2] - The fund manager, Liang Hao, has a tenure of 14 years and 204 days, with a total asset scale of 10.837 billion CNY, achieving the best fund return of 359.7% and the worst return of -31.55% during his tenure [2]